Home » Articles posted by administrator
Author Archives: administrator
Brand CEO Alan Green talks Tertiary Minerals (TYM), Trifast (TRI) & Burford Capital (BUR) on VOX Markets podcast
Brand CEO Alan Green discusses Tertiary Minerals (TYM), Trifast (TRI) & Burford Capital (BUR) with Justin Waite on the VOX Markets podcast. The interview is 28 minutes, 27 seconds in.
Tertiary Minerals (TYM) – Acquisition Opportunities
Tertiary Minerals plc, the AIM traded company building a strategic position in the fluorspar sector, is pleased to provide an update on its current business strategy.
The Company has made considerable progress in recent years developing its 100% owned fluorspar projects, progressing through the development cycle from discovery towards commercial production. A number of key issues have however resulted in delays to the development of our most advanced project, Storuman in Sweden, which are highlighted below:
- Poor stock market conditions for junior exploration/development companies
- Continued poor global market conditions for fluorspar
- Recent new case law established in Sweden changing the way Mine Permits are granted (Refer to previous RNS dated 13 & 15 December 2016)
Whilst the Company remains on track with its fluorspar strategy and the development of its fluorspar assets, it recognises the benefit of finding projects capable of generating revenue and profits in a shorter timescale than is achievable with the current portfolio of projects. With this in mind the Company is currently evaluating a number of complementary projects for acquisition with near term sustained revenue and profit potential.
Further news will be announced on the progress of evaluation as and when it becomes available.
Commenting today, Managing Director, Richard Clemmey said: “We are pleased to have started the evaluation process on a number of acquisition opportunities with the potential to transform the Company into being one with sustainable revenues in the near term and which will complement our fluorspar assets currently in development.”
|
Enquiries
Tertiary Minerals plc Richard Clemmey, Managing Director Patrick Cheetham, Executive Chairman
|
+44 (0) 1625 838 679 |
|
SP Angel Corporate Finance LLP Nominated Adviser & Joint Broker Ewan Leggat/Lindsay Mair/Laura Harrison |
+44 (0) 20 3470 0470 |
|
Beaufort Securities Ltd Joint Broker Elliot Hance
|
+44 (0)20 7382 8300 |
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement
Notes to Editors
Tertiary Minerals plc (ticker symbol ‘TYM’) is an AIM-traded mineral exploration and development company building a significant strategic position in the fluorspar sector. Fluorspar is an essential raw material in the chemical, steel and aluminium industries. Tertiary controls two significant Scandinavian projects (Storuman in Sweden and Lassedalen in Norway) and a large deposit of strategic significance in Nevada, USA (MB Project).
CAUTIONARY NOTICE
The news release may contain certain statements and expressions of belief, expectation or opinion which are forward looking statements, and which relate, inter alia, to the Company’s proposed strategy, plans and objectives or to the expectations or intentions of the Company’s directors. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the control of the Company that could cause the actual performance or achievements of the Company to be materially different from such forward-looking statements. Accordingly, you should not rely on any forward-looking statements and save as required by the AIM Rules for Companies or by law, the Company does not accept any obligation to disseminate any updates or revisions to such forward-looking statements.
Proton beam therapy used in tumour treatment in UAE – The National UAE
An advanced form of radiotherapy that reduces the risk of side effects in cancer patients will be available in the UAE for the first time when a Dh220 million health centre opens in Abu Dhabi in 2018.
Proton beam therapy, which uses protons rather than X-rays, is regarded as a safer way to treat hard-to-reach tumours because it causes less damage to surrounding tissue. It is used to treat many forms of the disease in situations where conventional options are limited and radiotherapy presents unacceptable risks to patient health, said Dr Mohanad Diab, consultant medical oncologist at NMC Specialty in Abu Dhabi.
“These situations include eye and brain cancers, tumours close to the brainstem and spinal cord, prostate, liver, lung and breast cancers, and paediatric cancers. It is very useful for children and it is used most often to treat brain tumours in young children whose brains are still developing,” he said.
The proton beam therapy centre in Al Shahamh will be part of the Gulf International Cancer Centre.
“At least 200 patients at our centre will benefit from proton beam and if we are the only centre in the area, there will be patients coming from neighbouring countries,” said Dr Aly Abdel Razek, executive director and head of radiation oncology at GICC,
Oncologists from the GICC will be sent for training to the US – where there are about 25 centres offering this treatment – to learn about the technology.
Many children will be helped by the technique, said Dr Razek. He gave an example of when doctors are treating cancer in a child’s spinal cord, proton beams treat the problem area without affecting the heart or the lungs.
“About 10 to 20 per cent of the cancer patients who receive radiation therapy can benefit from the use of proton beam.”
Proton therapy is not widely available because of its high cost. There are only a limited number of centres in the world that can deliver the treatment.
At the moment, patients in the UK who require this type of radiotherapy are sent for treatment in the US, according to Cancer Research UK.
Full article here
Trifast (TRI) – Keep buying this quality growth play says VectorVest
Trifast plc (TRI.L) is a UK-based manufacturer and distributor of industrial fastenings. The Company provides design support and problem solving solutions to its customers. The Company designs, manufactures and distributes a range of plastic components, metal fasteners and fixings on a global basis to both distributors and original equipment manufacturer (OEM) assemblers. It has has six manufacturing sites in Asia and one in the United Kingdom; with a global logistics capability from approximately 25 business locations within the United Kingdom, Asia, Europe and the United States.
In November 2017, TRI reported record breaking half-year numbers, with strong underlying trading growth driving underlying PBT 20.3% higher to £9.9m, on revenues 14.9% higher at £89.7m. Diluted EPS rose by 24.8% to 5.33p, and the group increased the interim dividend by 25% to 1p. Exec Chairman Malcolm Diamond said that the performance had put the group “firmly on track with our expectations to achieve another record breaking financial year.” A further trading update is due in early Q2.
The Trifast growth story had initially been identified by VectorVest during 2016, and on September 21 2016, we published a buy note for the group at 152p. The stock has powered higher since that time, driven by strong earnings growth, and with a trading update due at the end of Q1 2017, TRI is still flagged up as a quality investment opportunity across a number of VectorVest metrics. Value is still calculated at 220p, so currently trading at 213p, the stock has to be considered as fairly valued. Our attention though is drawn to the Relative Safety (RS) metric, an indicator of risk. Here TRI scores an RS rating of 1.38, which is very good on a scale of 0.00 to 2.00. Also highly significant is the VST-Vector (VST), the master indicator for ranking every stock in the VectorVest database, computed from the square root of a weighted sum of the squares of Relative Value (RV), RS, and Relative Timing (RT). Here TRI scores 1.32, which is very good on a scale of 0.00 to 2.00.
The weekly chart of Trifast above shows the gains over the past 6 years. The green line above the price is the VectorVest valuation of the share while the blue line in the window below the price shows earnings per share (EPS). EPS is growing strongly which is driving the share price upwards with increasing momentum. Technically the speed of the price (or momentum) should slow down prior to a turn in the price and there is no sign of that on the chart at the moment.
Summary: TRI has delivered a 38% gain since our September buy note. While the stock is now fairly valued at 213p, the prospect of a record FY performance coupled with the consistently high scores across key VectorVest metrics once again highlights TRI as a quality growth play. Keep Buying.
Dr David Paul
January 10th 2017
Readers can examine trading opportunities on TRI and a host of other similar stocks for a single payment of £5.95. This gives access to the VectorVest Risk Free 5-week trial, where members enjoy unlimited access to VectorVest UK & U.S., plus VectorVest University for on-demand strategies and training. Link here to view.
FREE! For free VectorVest analysis on any stock, go to this link here
VectorVest Unisearch
On VectorVest a simple search using the Unisearch tool will quickly find shares that are undervalued with good fundamentals that have just issued a Buy recommendation. This will give the active trader a short list of many high probability trading opportunities each week. Traders now have the opportunity to spend five weeks discovering VectorVest’s unique simplicity, automation and independent guidance. Just £5.95 buys a 5 week trial to enable deep exploration, or how the system can assist in smarter trading in as little as 10 minutes a day. Powerful tools. Proven strategies. Unique Perspectives.
Link here for more info and to set up a trial.
European Financial Publishing Limited T/A VectorVest UK (VectorVest) is authorised and regulated by the Financial Conduct Authority under register number 543038. You should remember that the value of investments and the income derived therefrom may fall as well as rise and you may not get back the amount that you invest. Past performance is not a reliable guide to the future. This material is directed only at persons in the UK and is not an offer or invitation to buy or sell securities. If investors are in any doubt of the suitability of an investment given their individual circumstances, they are recommended to contact an investment manager or independent financial adviser who may be able to provide tailored advice. Opinions expressed whether in general or both on the performance of individual securities and in a wider economic context represent the views of VectorVest at the time of preparation. They are subject to change and should not be interpreted as investment advice. VectorVest and connected companies, clients, directors, employees and other associates, may have a position in any security, or related financial instrument, issued by a company or organisation mentioned on this site. European Financial Publishing Limited is a company incorporated in Scotland under Company Number SC357322 with its registered address at Exchange Tower, 19 Canning Street, Edinburgh EH3 8EH. Email: support@VectorVest.com
Brand CEO Alan Green discusses IG Group (IGG), Premier Oil (PMO) & Angus Energy (ANGS) on Vox Markets podcast
Brand CEO Alan Green discusses IG Group (IGG), Premier Oil (PMO) & Angus Energy (ANGS) with Justin Waite on the Vox Markets podcast. The interview is 13 minutes 55 seconds in.
Buy Premier Oil (PMO) ahead of Jan 12 trading statement says VectorVest
Premier Oil plc (PMO.L) engages in the exploration, development, and production of oil and gas properties. The Company’s operations are located and managed in six business units: the Falkland Islands, Indonesia, Pakistan (including Mauritania), the United Kingdom, Vietnam and the Rest of the World. In total, the Company manages approximately 760 million barrels of oil equivalent (mmboe). The Company has production rates of over 90 thousand barrels of oil equivalent per day (kboepd). The Company focuses on producing 68 to 73 kboepd. The Company’s four-well North Falklands Basin campaign targets multiple stacked fans in PL004 and PL032 using the Eirik Raude rig. The Company owns an interest in over two licenses, such as Natuna Sea Block A and Kakap.
On November 17th 2016, PMO updated on trading and half year results. The group reported an average production during the first half of 69 kboepd year-to-date. At the time of results, the current run rate was >80 kboepd, and PMO confirmed it was on track to meet previously increased full year guidance of 68-73 kboepd. CEO Tony Durrant said the company was “continuing to deliver operationally against a challenging commodity price backdrop.” He pointed to how PMO was “benefiting from a step change in production with a significantly lower cost base.”
The group debt position is currently being renegotiated with its lenders, and PMO expects to update shareholders in a further update on January 12 2017.
The potential valuation upside in PMO had been highlighted by VectorVest financial and technical metrics when the stock pulled back to around 50p in November 2016. The VectorVest valuation metric highlights a value of 95.53p per share, meaning it remains undervalued at the current 75.50p per share.
The stock also demonstrates a forecasted Earnings Growth Rate (GRT) of 21.00%, which VectorVest considers to be excellent. A word of caution – the Relative Safety metric (RS) is 0.94, which is fair on a scale of 0.00 to 2.00. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database.
The chart of PMO.L is shown above with the price in candlestick format. The green line above the price is the VectorVest valuation while the blue line in the window below the price is earnings per share (EPS).
Presently the share is trying to break out of an inverted head and shoulders reversal. The target from this pattern should take the share to around 110.
Summary: Although not without a degree of risk, VectorVest sees significant upside potential in PMO, and currently considers the stock as undervalued. In addition, the trading statement and progress on debt negotiation update due on January 12 2017, is expected to be a key trigger event for the share price. Buy.
Dr David Paul
January 5th 2017
Readers can examine trading opportunities on DRX and a host of other similar stocks for a single payment of £5.95. This gives access to the VectorVest Risk Free 5-week trial, where members enjoy unlimited access to VectorVest UK & U.S., plus VectorVest University for on-demand strategies and training. Link here to view.
FREE! For free VectorVest analysis on any stock, go to this link here
VectorVest Unisearch
On VectorVest a simple search using the Unisearch tool will quickly find shares that are undervalued with good fundamentals that have just issued a Buy recommendation. This will give the active trader a short list of many high probability trading opportunities each week. Traders now have the opportunity to spend five weeks discovering VectorVest’s unique simplicity, automation and independent guidance. Just £5.95 buys a 5 week trial to enable deep exploration, or how the system can assist in smarter trading in as little as 10 minutes a day. Powerful tools. Proven strategies. Unique Perspectives.
Link here for more info and to set up a trial.
European Financial Publishing Limited T/A VectorVest UK (VectorVest) is authorised and regulated by the Financial Conduct Authority under register number 543038. You should remember that the value of investments and the income derived therefrom may fall as well as rise and you may not get back the amount that you invest. Past performance is not a reliable guide to the future. This material is directed only at persons in the UK and is not an offer or invitation to buy or sell securities. If investors are in any doubt of the suitability of an investment given their individual circumstances, they are recommended to contact an investment manager or independent financial adviser who may be able to provide tailored advice. Opinions expressed whether in general or both on the performance of individual securities and in a wider economic context represent the views of VectorVest at the time of preparation. They are subject to change and should not be interpreted as investment advice. VectorVest and connected companies, clients, directors, employees and other associates, may have a position in any security, or related financial instrument, issued by a company or organisation mentioned on this site. European Financial Publishing Limited is a company incorporated in Scotland under Company Number SC357322 with its registered address at Exchange Tower, 19 Canning Street, Edinburgh EH3 8EH. Email: support@VectorVest.com
IMC Exploration Group (IMCP) – AGM and Share Placement
IMC Exploration Group (IMCP) – AGM & SHARE PLACEMENT
At the recent Annual General Meeting of IMC, all the resolutions put to shareholders were passed.
The board of IMC Exploration Group plc are also pleased to announce that they have raised £150,000 by way of a Placing and Subscription of 15,000,000 new ordinary shares of €0.01 each in the Company, at a price of 1p per share. Two directors, Liam McGrattan and Nial Ring have subscribed £50,000. Global Resource Investment Trust plc has subscribed a further £50,000.
Following this issue of new ordinary shares, the total number of ordinary shares in issue is 122,816,719.
Chairman, Liam McGrattan commented “IMC continues to make solid progress in its exploration and corporate activities. We look forward to the coming year with enthusiasm.”
Contact Details:
IMC Exploration Group PLC
Liam McGrattan
Tel. +353 872745427
Keith Bayley Rogers & Co. Limited
Hugh Oram
Tel: +44 207 464 4090
Markets and Macro – Outlook for 2017 – Panmure Gordon
<img class="alignnone wp-image-4849" src="http://www slimming products.branduk.net/wp-content/uploads/2017/01/Buik0317-300×287.jpg” alt=”Buik0317″ width=”495″ height=”474″ srcset=”http://www.branduk.net/wp-content/uploads/2017/01/Buik0317-300×287.jpg 300w, http://www.branduk.net/wp-content/uploads/2017/01/Buik0317-768×735.jpg 768w, http://www.branduk.net/wp-content/uploads/2017/01/Buik0317.jpg 815w” sizes=”(max-width: 495px) 100vw, 495px” />
Brand CEO Alan Green with Zak Mir on TipTV – Prospects for 2017 – Reasons to be Cheerful
Brand CEO Alan Green with Zak Mir on TipTV – Prospects for 2017 – Reasons to be Cheerful, plus stocks including Marks & Spencer (MKS) and IG Group (IGG). Link here
Advanced Oncotherapy (AVO) – Additional Director Dealing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 87 pence per Ordinary Share.
Following this transaction, Dr Vanni now holds 823,946 Ordinary Shares representing 1.14% of the issued share capital of the Company.
|
Advanced Oncotherapy Plc |
|
|
Dr. Michael Sinclair, Executive Chairman |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CEO |
|
|
Stockdale Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
Stifel Nicolaus Europe (Joint Broker) |
|
|
Jonathan Senior / Ben Maddison |
Tel: +44 20 7710 7600 |
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.